GO43860

A phase Ia/Ib, open-label, multicenter, dose-escalation study to evaluate the safety, pharmacokinetics, and activity of RO7502175 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.

  • Code NKI: M22GOR
  • Code firma: GO43860
  • Code clinicaltrials.gov: NCT05581004

Principal Investigator

Dr. N. Steeghs

Drugs

RO7502175 (anti-CCR8 antilichaam) + atezolizumab

  • Expansion cohort A for melanoma PDL1+ – open
  • Expansion cohort A for PDL-1+ NSCLC – closed
  • Expansion cohort A for HNSCC – open
  • Expansion cohort B for PDL1+ RCC – open
  • Expansion cohort B for PDL-1+ NSCLC – open
  • Expansion cohort B for melanoma (no PDL1 threshold) – open
  • Expansion cohort B for RCC (no PDL1-cutoff) – open
  • Expansion cohort B for CPI-ervaren NSCLC – closed
  • Expansion cohort B for CPI-ervaren HNSCC – closed
  • CPI-naive NSCLC cohort – open
  • Expansion serial biopsy cohort for all tumor types – open

Summary

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.

Read more on clinicaltrials.gov